'Clinical efficacy' presentation slideshows

Treatment of Acute Otitis Media With Azithromycin

Treatment of Acute Otitis Media With Azithromycin. Michael Dunne, MD Vice President Clinical Development, Infectious Diseases Pfizer Global Research and Development. Azithromycin for Acute Otitis Media Rationale. Bactericidal against the pathogens responsible for AOM.

1.9k views • 119 slides

Pleconaril for Treatment of the Common Cold FDA Antiviral Drugs Advisory Committee Meeting March 19, 2002

Pleconaril for Treatment of the Common Cold FDA Antiviral Drugs Advisory Committee Meeting March 19, 2002. Agenda. Introduction Mark McKinlay, PhD Impact of the Common Cold Frederick Hayden, MD Preclinical Profile and Clinical Pharmacology Mark McKinlay, PhD Clinical Efficacy and Safety

1.35k views • 78 slides

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer

951 views • 75 slides

The Clinical Evidence Base of Homeopathy

The Clinical Evidence Base of Homeopathy. Peter Fisher FRCP, FFHom Clinical Director and Director of Research Royal London Homoeopathic Hospital. Comprehensive Systematic Reviews & Meta-analyses of homeopathy. Kleijnen BMJ 1991 81/105 interpretable studies positive

974 views • 73 slides

Antibiotic Update 2009

Antibiotic Update 2009. Michael S. Bronze, MD Professor and Chair Department of Medicine, OUHSC. Objectives. To briefly review some of the current issues with antibiotics To discuss several newer agents To discuss several clinical situations in which newer agents may have an expanding role

486 views • 47 slides

Comparison of Preseason and Postseason ImPACT Scores in NCAA College Soccer Players

Comparison of Preseason and Postseason ImPACT Scores in NCAA College Soccer Players. Demetri Menegos, D.O. April 16, 2010 Sports Medicine Fellow Atlantic Health--Overlook Mount Sinai School of Medicine. Background.

501 views • 40 slides

Drug Dosage and Clinical Responses

Drug Dosage and Clinical Responses. September 12, 2007 Frank F. Vincenzi. Antagonism Potency Clinical efficacy Slope of D-R curve Quantal response ED50, LD50, TI Synergism Summation. Tolerance Tachyphylaxis Idiosyncrasy Drug allergy Therapeutic/side effects Adverse effects

486 views • 34 slides

Control of Microorganisms by Antibiotics

Control of Microorganisms by Antibiotics. Weinberg, chapter 11. Properties of an Ideal Antibiotic. Bacterial specificity Should not produce resistant strains Does not cause allergy or toxicity Does not cause other side effects Does not eliminate normal oral flora Cost effective

1.24k views • 32 slides

Pharmacology, Pharmacy and Herbal medicine

Pharmacology, Pharmacy and Herbal medicine. Lecture 4: Plants and the nervous system. Spot Test. Questions. 1. What are the following medications indicated for and how do they work? Captopril (3) Verapamil (3) Propanalol (3)

614 views • 31 slides

Back Pain

Back Pain. 2 nd most common cause for office visit 60-80% of population will have lower back pain at some time in their lives Each year, 15-20% will have back pain Most common cause of disability for persons < 45 years 1% of US population is disabled Costs to society: $20-50 billion/year.

1.09k views • 30 slides

Prospective validation of the Wireless Vital Signs Monitor System

587 views • 29 slides

CLUSTER IMMUNOTHERAPY

CLUSTER IMMUNOTHERAPY. Overview. Main difference: time required to reach maintenance dose. Definition. Cluster immunotherapy Accelerated build-up schedule

474 views • 29 slides

Topic 1 : How do pathogen/pest populations respond to deployment of host resistance?

614 views • 28 slides

Which Patients for Subcutaneous Immunotherapy?

Which Patients for Subcutaneous Immunotherapy?. Harold S. Nelson. MD Professor of Medicine National Jewish Heath University of Colorado Denver School of Medicine Denver, Colorado, USA. Which Patients for Immunotherapy?. Appropriate clinical manifestations.

477 views • 28 slides

MANAGING SUBTHERAPEUTIC AED LEVELS Edwin Kuffner, MD, FACEP Rocky Mountain Poison and Drug Center Denver, Colorado

MANAGING SUBTHERAPEUTIC AED LEVELS Edwin Kuffner, MD, FACEP Rocky Mountain Poison and Drug Center Denver, Colorado. Case Presentation. 35-year old, otherwise healthy, male presents to ED after having a seizure PMH: seizures since childhood, last 2 years prior

414 views • 22 slides

Licensing a New Vaccine on the Basis of Surrogate Endpoints: A Practical Example

Licensing a New Vaccine on the Basis of Surrogate Endpoints: A Practical Example. Robert C. Kohberger, Ph.D. VP Planning and Project Management. 19 September, 2003. Correlates and Surrogates?. Nomenclature:

342 views • 16 slides

Coloplast- An update on Trans- Anal Irrigation

Coloplast- An update on Trans- Anal Irrigation. Peristeen. Agenda. Health Economic Burden of Bowel Trans Anal Irrigation- An Intro Patient Types & Experience Efficacy and Safety Update Coloplast Patient Support Programmes. Bowel Problems are extremely common.

659 views • 14 slides

Proportion of Resistant Pnc (%) to Various Antibiotic Categories - MEF Southern Israel 1992 - 2002

192 views • 10 slides

Amani Thomas Mori, Eliangiringa Amos Kaale

Priority setting for implementation of Artemisinin based combination therapy policy in Tanzania: Evaluation against accountability for reasonableness framework . Amani Thomas Mori, Eliangiringa Amos Kaale. Introduction.

247 views • 9 slides

ART Program Management under Universal Health Coverage

201 views • 0 slides